Overview

  • Product name

    Anti-TGF beta Receptor II antibody [MM0056-4F14]
    See all TGF beta Receptor II primary antibodies
  • Description

    Mouse monoclonal [MM0056-4F14] to TGF beta Receptor II
  • Host species

    Mouse
  • Specificity

    ab78419 detects TGF beta Receptor II. No cross reactivity was found to rTGF beta Receptor III.
  • Tested applications

    Suitable for: ICC/IF, IHC-Fr, Flow Cyt, IHC-Pmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant human TGF beta Receptor II extracellular domain

Properties

Applications

Our Abpromise guarantee covers the use of ab78419 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/50.
IHC-Fr Use at an assay dependent concentration.
Flow Cyt Use 1µg for 106 cells.

ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

IHC-P 1/50 - 1/200.

Target

  • Function

    Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.
  • Involvement in disease

    Defects in TGFBR2 are the cause of hereditary non-polyposis colorectal cancer type 6 (HNPCC6) [MIM:614331]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases.
    Defects in TGFBR2 are a cause of esophageal cancer (ESCR) [MIM:133239].
    Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 1B (LDS1B) [MIM:610168]. LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
    Defects in TGFBR2 are the cause of Loeys-Dietz syndrome type 2B (LDS2B) [MIM:610380]. An aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients. Note=TGFBR2 mutations Cys-460 and His-460 have been reported to be associated with thoracic aortic aneurysms and dissection (TAAD). This phenotype, also known as thoracic aortic aneurysms type 3 (AAT3), is distinguised from LDS2B by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit descending aortic disease and aneurysms of other arteries (PubMed:16027248), they have been considered as LDS2B by the OMIM resource.
  • Sequence similarities

    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications

    Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.
  • Cellular localization

    Cell membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • AAT3 antibody
    • FAA3 antibody
    • LDS1B antibody
    • LDS2 antibody
    • LDS2B antibody
    • MFS2 antibody
    • RIIC antibody
    • TAAD2 antibody
    • TbetaR II antibody
    • TbetaR-II antibody
    • TGF beta receptor type 2 antibody
    • TGF beta receptor type II antibody
    • TGF beta receptor type IIB antibody
    • TGF beta type II receptor antibody
    • TGF-beta receptor type II antibody
    • TGF-beta receptor type-2 antibody
    • TGF-beta type II receptor antibody
    • TGF-beta-R2 antibody
    • TGFB R2 antibody
    • TGFbeta - RII antibody
    • TGFbeta RII antibody
    • Tgfbr2 antibody
    • TGFR-2 antibody
    • TGFR2_HUMAN antibody
    • Transforming growth factor beta receptor II antibody
    • Transforming growth factor beta receptor type II antibody
    • Transforming growth factor beta receptor type IIC antibody
    • Transforming growth factor, beta receptor II (70/80kDa) antibody
    • transforming growth factor, beta receptor II alpha antibody
    • transforming growth factor, beta receptor II beta antibody
    • transforming growth factor, beta receptor II delta antibody
    • transforming growth factor, beta receptor II epsilon antibody
    • transforming growth factor, beta receptor II gamma antibody
    • Transforming growth factor-beta receptor type II antibody
    see all

Images

  • ab78419 at 1/200 dilution, staining TGF beta Receptor II in human placental tissue section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections).

  • Overlay histogram showing HepG2 cells stained with ab78419 (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab78419, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
    Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.
  • Immunohistochemical analysis of Human lung frozen tissue sections (A - alveolar macrophages, B - lung carcinoma), labeling TGF beta Receptor II with ab78419. Samples were fixed in HOPE and immunostained with ab78419 diluted 1/400 for 1 hour at 25°C.

    See Abreview

  • Immunofluorescence analysis of Human bronchial fibroblasts, staining TGF beta Receptor II with ab78419.

    Cells were fixed in paraformaldehyde, permeabilised in 0.1% Triton X-100 and blocked with 1% BSA. Samples were incubated with primary antibody and an AlexaFluor®-conjugated anti-mouse IgG was used as a secondary antibody.

References

This product has been referenced in:

  • Song K  et al. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells. Am J Cancer Res 8:792-809 (2018). Read more (PubMed: 29888103) »
  • Breunig C  et al. TGFß1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. Mol Oncol 12:1447-1463 (2018). Flow Cyt ; Human . Read more (PubMed: 30004628) »
See all 15 Publications for this product

Customer reviews and Q&As

1-7 of 7 Abreviews or Q&A

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (Human Bronchial Epithelial cells)
Specification
Human Bronchial Epithelial cells
Fixative
Formaldehyde
Permeabilization
No
Blocking step
Serum as blocking agent for 20 minute(s) · Concentration: 1% · Temperature: 20°C

Abcam user community

Verified customer

Submitted Nov 09 2012

Answer

Thank you for your message and for providing this further information.

I am sorry to hear the suggestions made have not improved the results on this occasion. I appreciate the time you have spent on these experiments, and would like to offer a refund or credit note in compensation (providing the product has been purchased in the last6 months). In order to arrange this, I would appreciate if you could confirmthe Abcamorder referencenumber and date of purchase?

Thank you for your continued cooperation. I look forward to hearing from you with details of how you would like to proceed.

Read More

Answer

Thank you for taking the time to complete our questionnaire and contact us. I am sorry to hear you have had difficulty obtaining satisfactory results from this antibody.

The details you have kindly provided will enable us to investigate this case for you and this is also helpful in our records for monitoring of quality.

I would like to reassure you that ab16793 and ab78419 are tested and covered by our 6 month guarantee for use in WBand human samples. In the event that a product is not functioning in the applications cited on the product data sheet, we will be pleased to provide a credit note or free of charge replacement.

Reviewing this case, I would appreciate if you can confirm some further details:

1. Please confirm the order number and date of purchase?

2. Is the secondary antibody working well with other primary antibodies?

3. Were the samples reduced and denatured?

4. What level of expression of DCC and TGF beta Receptor II are you expecting in these samples? What positive controls have been used?

I hope this information is helpful, thank you for your cooperation. Should the suggestions not improve the results, please do not hesitate to contact me again with the further requested details.

Read More

Question
Answer

Thank you for contacting us.

The lab sent me the following antigen retrieval information.

We used the following conditions:



1) Protease Type XXIV, 0.05% solution (w/v) dissolved in 0.1 M phosphate buffer.


2) Room temperature for 15˜30mins



I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Use our products? Submit an Abreview. Earn rewards!
https://www.abcam.com/abreviews

Read More

Question
Answer

Thank you for your phone call.

DISCOUNT CODE: xxx
Expiration date: xxx


I am very pleased to hear you would like to accept our offer and test ab78419 in ICC/IF. This code will give you: 1 free PRIMARY ANTIBODYbefore the expiration date. To redeem this offer, please submit an Abreview for ICC/IF and include this code in the “Additional Comments” section so we know the Abreview is for this promotion. For more information on how to submit an Abreview, please visit the site: www.abcam.com/Abreviews.

Remember, we publish both positive and negative Abreviews on our datasheets so please submit the results of your tests. The code will be active once the Abreview has been submitted and can be redeemed in one of the following ways: 1) Call to place your order and mention the code to our customer service department; 2) Include the code in your fax order; 3) Place your order on the web and enter the promotional code.

Any feedback that you can provide will be greatly appreciated, whether positive or negative. If you have any further questions, please do not hesitate to contact us. We look forward to receiving your Abreview and wish you luck with your research.

The terms and conditions applicable to this offer can be found here: https://www.abcam.com/collaborationdiscount.

Read More
Application
Immunohistochemistry (Frozen sections)
Sample
Human Tissue sections (Lung tissue)
Specification
Lung tissue
Fixative
HOPE
Permeabilization
No
Blocking step
(agent) for 5 minute(s) · Concentration: 100% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Aug 02 2011

Application
Immunohistochemistry (Frozen sections)
Sample
Mouse Tissue sections (Brain)
Specification
Brain
Fixative
Paraformaldehyde
Permeabilization
Yes - PBS Tween 0.1% for washes and PBS Triton 0.5% for 1h before blocking
Blocking step
2% BSA + 4% Goat serum as blocking agent for 1 hour(s) and 30 minute(s) · Concentration: 6% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Nov 01 2010

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up